Published in Eur Heart J on April 08, 2005
Mannan-binding lectin plasma levels in leprosy: deficiency confers protection against the lepromatous but not the tuberculoid forms. Clin Exp Immunol (2006) 0.93
Mechanisms involved in antibody- and complement-mediated allograft rejection. Immunol Res (2010) 0.88
Deficiency of complement factor MBL in a patient required cardiac surgery after an acute myocardial infarction with underlining chronic lymphocytic leukemia. Int J Cardiol (2008) 0.85
Mannan-binding lectin in cardiovascular disease. Biomed Res Int (2014) 0.81
Mannose-binding lectin deficiency linked to cytomegalovirus (CMV) reactivation and survival in lung transplantation. Clin Exp Immunol (2011) 0.79
Low levels of mannan-binding lectin or ficolins are not associated with an increased risk of cytomegalovirus disease in HIV-infected patients. PLoS One (2013) 0.78
Subclinical rejection in renal transplants is associated with low serum mannose-binding lectin levels. Kidney Int Suppl (2011) (2011) 0.76
Mannose-Binding Lectin: Biologic Characteristics and Role in the Susceptibility to Infections and Ischemia-Reperfusion Related Injury in Critically Ill Neonates. J Immunol Res (2017) 0.75
Activation of complement factor B contributes to murine and human myocardial ischemia/reperfusion injury. PLoS One (2017) 0.75
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med (2006) 7.28
Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A (2003) 3.98
The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res (2013) 3.92
Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol (2006) 2.96
Molecular characterization of NF-HEV, a nuclear factor preferentially expressed in human high endothelial venules. Am J Pathol (2003) 2.72
Primary antitumor immune response mediated by CD4+ T cells. Immunity (2005) 2.72
Adipose tissue distribution in relation to insulin sensitivity and inflammation in Pakistani and Norwegian subjects with type 2 diabetes. Scand J Clin Lab Invest (2014) 2.63
Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT (2003) 2.41
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol (2007) 2.40
Rewarming after hypothermia after cardiac arrest shifts the inflammatory balance. Crit Care Med (2012) 2.26
Up-regulation of NOTCH4 gene expression in bipolar disorder. Am J Psychiatry (2012) 2.04
Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation (2007) 2.00
Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: a prospective, randomized trial. J Clin Endocrinol Metab (2007) 1.99
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J (2012) 1.93
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol (2004) 1.88
C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J (2009) 1.79
Plasma C-reactive protein as a marker of cardiac allograft vasculopathy in heart transplant recipients. J Am Coll Cardiol (2003) 1.77
Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol (2008) 1.76
Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord (2009) 1.74
Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure. Eur Heart J (2009) 1.71
Cerebral outcome in adult patients treated with extracorporeal membrane oxygenation. Ann Thorac Surg (2006) 1.68
CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation (2008) 1.64
Relation of osteoprotegerin to coronary calcium and aortic plaque (from the Dallas Heart Study). Am J Cardiol (2006) 1.63
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Absence of enhanced systemic inflammatory response at 18 weeks of gestation in women with subsequent pre-eclampsia. BJOG (2002) 1.61
Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood (2004) 1.61
Increased circulating mitochondrial DNA after myocardial infarction. Int J Cardiol (2012) 1.58
Peptidoglycan of Staphylococcus aureus causes inflammation and organ injury in the rat. Crit Care Med (2004) 1.57
Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood (2010) 1.56
The peripheral blood mononuclear cell microRNA signature of coronary artery disease. Biochem Biophys Res Commun (2010) 1.55
A role for CCR4 in development of mature circulating cutaneous T helper memory cell populations. J Exp Med (2005) 1.54
Cytokine networks are pre-activated in T cells from HIV-infected patients on HAART and are under the control of cAMP. AIDS (2004) 1.54
Effect of exercise training on skeletal muscle fibre characteristics in men with chronic heart failure. Correlation between skeletal muscle alterations, cytokines and exercise capacity. Int J Cardiol (2002) 1.53
Effect of perfusion temperature on the inflammatory response during pediatric cardiac surgery. Ann Thorac Surg (2008) 1.52
Physical activity patterns and exercise performance in cardiac transplant recipients. J Cardiopulm Rehabil (2003) 1.52
Noninvasive assessment of myocardial fibrosis in patients with obstructive hypertrophic cardiomyopathy. Heart (2013) 1.51
Rapid chemokine secretion from endothelial cells originates from 2 distinct compartments. Blood (2004) 1.50
Effect of exercise training in patients with heart failure: a pilot study on autonomic balance assessed by heart rate variability. Eur J Cardiovasc Prev Rehabil (2004) 1.50
Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer. Nat Commun (2011) 1.49
Pre-transplant Toxoplasma gondii seropositivity among heart transplant recipients is associated with an increased risk of all-cause and cardiac mortality. J Am Coll Cardiol (2007) 1.48
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol (2006) 1.47
Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial. Transplantation (2011) 1.46
Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol (2008) 1.45
Activated leukocyte cell adhesion molecule and prognosis in acute ischemic stroke. Stroke (2011) 1.44
Gene expression profiling identifies ESRP1 as a potential regulator of epithelial mesenchymal transition in somatotroph adenomas from a large cohort of patients with acromegaly. J Clin Endocrinol Metab (2012) 1.44
Effect of high-intensity interval training on progression of cardiac allograft vasculopathy. J Heart Lung Transplant (2013) 1.43
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis. Circulation (2009) 1.41
The molecular basis for oat intolerance in patients with celiac disease. PLoS Med (2004) 1.40
[Should patients with severe sepsis be treated with activated protein C?]. Tidsskr Nor Laegeforen (2004) 1.39
[A 52-year old woman with fever and respiratory failure]. Tidsskr Nor Laegeforen (2009) 1.39
[Treatment of combined carotid and cardiac disease]. Tidsskr Nor Laegeforen (2005) 1.39
[A patient with aortic stenosis and reduced left ventricular function]. Tidsskr Nor Laegeforen (2009) 1.39
Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure. Circulation (2005) 1.38
[Not Available]. Tidsskr Nor Laegeforen (2016) 1.38
[Dramatic case report caused by a rare bacteria]. Tidsskr Nor Laegeforen (2010) 1.38
EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail (2013) 1.37
Identification of NDM-1-producing Enterobacteriaceae in Norway. J Antimicrob Chemother (2010) 1.37
The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant (2002) 1.36
An international serum standard for application in assays to detect human complement activation products. Mol Immunol (2013) 1.34
EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail (2010) 1.32
Stromal cell-derived factor-1alpha in unstable angina: potential antiinflammatory and matrix-stabilizing effects. Circulation (2002) 1.32
Systemic inflammation in heart failure--the whys and wherefores. Heart Fail Rev (2006) 1.30